The Spondylitis Association of America, in partnership with members of its Medical and Scientific Advisory Board, has spearheaded research into the possible impact spondyloarthritis, and medications used for spondyloarthritis, may have on COVID-19.
Understanding the effects of spondyloarthritis, and the medications used in treating it, on COVID-19 is crucial for patients, doctors, and researchers alike. Taking part in this research will help answer critical questions for the benefit of everyone in the spondyloarthritis community.
This survey will take an estimated 10-15 minutes to complete. If you take part, you will be asked to answer the questions in this survey, and in follow up surveys every four weeks for an estimated six months. You can opt out at any time.
Precaution has been taken to protect your personal information as you answer these questions. All your responses are confidential, and your personal information will be protected. We do need your email address so that we can follow up with you. Only the survey platform will have access to your information, including your email address. SAA respects and protects our community’s privacy and does not sell personal data.
Who is eligible to take part?
- We are currently looking for those with a diagnosis of spondyloarthritis made by a physician (those with ankylosing spondylitis, non-radiographic axial spondyloarthritis, psoriatic arthritis, arthritis with inflammatory bowel disease, peripheral spondyloarthritis, undifferentiated spondyloarthritis, reactive arthritis, or juvenile spondyloarthritis).
- During phase two of the survey, we will include interested household members of those with spondyloarthritis (to act as a control group for the survey.)
- This survey is open to people throughout the world, and we invite everyone who is eligible to take part.
What is my time commitment should I decide to take part?
- The initial time commitment is an estimated 10-15 minutes for the current survey. Four weeks after you complete this first survey, you will be asked to complete a follow up survey. We will continue to ask for your permission to contact you again every four weeks, for the next six months. You can, of course, opt out at any time.
This survey has been reviewed and approved by the IRB of the Oregon Health & Science University. The Principal Investigator of this study is James Rosenbaum, MD.